Dynacure’s Agreement With Nippon Shinyaku

McDermott Will & Emery advised Dynacure on the deal.

Dynacure, a clinical-stage company focused on developing and commercializing innovative therapies to transform the lives of patients with rare diseases who have few or no treatment options, signed a long-term strategic development and commercialization agreement of DYN101 with Nippon Shinyaku Co., Ltd in Japan. Dynacure will retain rights to rest-of-world development and commercialization. Dynacure will receive an initial payment of USD 5 million.

Under the terms of the agreement, Nippon Shinyaku has obtained an exclusive option to acquire development and commercial rights in the territory of Japan from Dynacure to develop DYN101, an investigational antisense oligonucleotide product candidate designed to be a disease-modifying medicine for the treatment of the majority of Myotubular and Centronuclear Myopathies (CNM). 

DYN101 is currently being evaluated in a Phase 1/2 clinical trial, UNITE-CNM (DYN101-C101), at multiple clinical sites in Europe. DYN101 has been granted orphan drug designation by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and rare pediatric disease designation by the FDA. There is currently no FDA-, EMA- or Pharmaceuticals and Medical Devices Agency (PMDA)- approved therapeutic treatment for CNM.

The McDermott’s team for Dynacure included Emmanuelle Trombe (Picture), partner and Katya Ascher, Counsel.

Involved fees earner: Katya Ascher – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery;

Law Firms: McDermott Will & Emery;

Clients: Dynacure;